122 related articles for article (PubMed ID: 26635878)
1. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
Davis KL; Côté I; Kaye JA; Mendelson E; Gao H; Perez Ronco J
Adv Hematol; 2015; 2015():848473. PubMed ID: 26635878
[TBL] [Abstract][Full Text] [Related]
2. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
[TBL] [Abstract][Full Text] [Related]
3. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Mead AJ; Butt NM; Nagi W; Whiteway A; Kirkpatrick S; Rinaldi C; Roughley C; Ackroyd S; Ewing J; Neelakantan P; Garg M; Tucker D; Murphy J; Patel H; Bains R; Chiu G; Hickey J; Harrison C; Somervaille TCP
Ther Adv Hematol; 2022; 13():20406207221084487. PubMed ID: 35371428
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.
Góra-Tybor J; Gołos A; Mikulski D; Helbig G; Sacha T; Lewandowski K; Niesiobędzka-Krężel J; Bieniaszewska M; Wysogląd H; Grzybowska-Izydorczyk O; Seferyńska I; Sobas M; Czyżewska M; Michalska A; Sawicki W; Mazur M; Hus M; Bodzenta E; Olszewska-Szopa M; Włodarczyk M; Patkowska E; Świstek W; Jamroziak K
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e19-e26. PubMed ID: 36396583
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
Ellis MH; Lavi N; Mishchenko E; Dally N; Lavie D; Courevitch A; Gutwein O; Bulvik S; Braester A; Chubar E; Tavor S; Duek A; Kirgner I; Koren-Michowitz M
Leuk Res; 2015 Aug; ():. PubMed ID: 26364797
[TBL] [Abstract][Full Text] [Related]
6. Real-life ruxolitinib experience in intermediate-risk myelofibrosis.
Arikan F; Toptas T; Atagunduz IK; Ercan T; Oruc O; Yilmaz F; Tuglular T
Blood Res; 2021 Dec; 56(4):322-331. PubMed ID: 34916339
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Passamonti F; Lou Y; Chevli M; Abraham P
Future Oncol; 2023 Nov; ():. PubMed ID: 37991002
[TBL] [Abstract][Full Text] [Related]
8. Trend of circulating CD34
Iurlo A; Galli N; Bucelli C; Artuso S; Consonni D; Cattaneo D
Br J Haematol; 2023 Feb; 200(3):315-322. PubMed ID: 36266779
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.
Duminuco A; Nardo A; Garibaldi B; Vetro C; Longo A; Giallongo C; Di Raimondo F; Palumbo GA
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556033
[TBL] [Abstract][Full Text] [Related]
10. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Tang D; Abraham P; Lord-Bessen J; Rose S; Guo S; Liao W; Mesa RA
Hemasphere; 2021 May; 5(5):e562. PubMed ID: 33969275
[TBL] [Abstract][Full Text] [Related]
11. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.
Barosi G; Rosti V; Gale RP
Onco Targets Ther; 2015; 8():1091-102. PubMed ID: 26056473
[TBL] [Abstract][Full Text] [Related]
12. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Palandri F; Palumbo GA; Bonifacio M; Tiribelli M; Benevolo G; Martino B; Abruzzese E; D'Adda M; Polverelli N; Bergamaschi M; Tieghi A; Cavazzini F; Ibatici A; Crugnola M; Bosi C; Latagliata R; Di Veroli A; Scaffidi L; de Marchi F; Cerqui E; Anaclerico B; De Matteis G; Spinsanti M; Sabattini E; Catani L; Aversa F; Di Raimondo F; Vitolo U; Lemoli RM; Fanin R; Merli F; Russo D; Cuneo A; Bacchi Reggiani ML; Cavo M; Vianelli N; Breccia M
Oncotarget; 2017 Oct; 8(45):79073-79086. PubMed ID: 29108288
[TBL] [Abstract][Full Text] [Related]
13. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
Tavares R; Souza CA; Paley C; Bouard C; Tiwari R; Pasquini R
Hematol Transfus Cell Ther; 2020; 42(1):46-53. PubMed ID: 31235325
[TBL] [Abstract][Full Text] [Related]
14. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
McMullin MF; Harrison CN; Niederwieser D; Demuynck H; Jäkel N; Gopalakrishna P; McQuitty M; Stalbovskaya V; Recher C; Theunissen K; Gisslinger H; Kiladjian JJ; Al-Ali HK
Exp Hematol Oncol; 2015; 4():26. PubMed ID: 26380150
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib for myelofibrosis.
Gu L; Su L; Chen Q; Xie J; Wu G; Yan Y; Liang B; Tan J; Tang N
Exp Ther Med; 2013 Mar; 5(3):927-931. PubMed ID: 23408184
[TBL] [Abstract][Full Text] [Related]
16. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
17. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib.
Stoeva V; Petrova G; Mitov K; Tachkov K
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513888
[TBL] [Abstract][Full Text] [Related]
18. Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Gerds AT; Lyons RM; Colucci P; Kalafut P; Paranagama D; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e532-e540. PubMed ID: 35256316
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib-A Real-Life Longitudinal Study.
Stoeva V; Mihaylov G; Mitov K; Petrova G; Tachkov K
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894452
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.
Manduzio P
Ther Clin Risk Manag; 2017; 13():169-177. PubMed ID: 28243106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
